Omnicell (OMCL) to Post Earnings on Thursday

Omnicell (NASDAQ:OMCL) will likely be posting its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Omnicell to post earnings of $0.48 per share and revenue of $310.2460 million for the quarter. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:30 AM ET.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. Omnicell had a net margin of 1.67% and a return on equity of 4.00%. The firm had revenue of $309.88 million for the quarter, compared to the consensus estimate of $304.02 million. During the same period in the previous year, the firm earned $0.26 EPS. The business’s revenue for the quarter was up 14.9% compared to the same quarter last year. On average, analysts expect Omnicell to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Omnicell Stock Performance

NASDAQ OMCL opened at $40.86 on Thursday. Omnicell has a 1 year low of $27.77 and a 1 year high of $55.00. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.50 and a quick ratio of 1.29. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of 92.87, a PEG ratio of 1.08 and a beta of 0.96. The company has a fifty day moving average price of $42.53 and a 200-day moving average price of $41.44.

Insider Transactions at Omnicell

In other news, EVP Nnamdi Njoku sold 3,090 shares of Omnicell stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $133,549.80. Following the completion of the transaction, the executive vice president owned 154,785 shares in the company, valued at $6,689,807.70. This trade represents a 1.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the sale, the executive vice president directly owned 112,783 shares in the company, valued at approximately $4,874,481.26. This trade represents a 4.27% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is owned by company insiders.

Hedge Funds Weigh In On Omnicell

Large investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP raised its stake in shares of Omnicell by 9.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,364,068 shares of the company’s stock valued at $71,985,000 after purchasing an additional 197,462 shares during the period. Wellington Management Group LLP boosted its stake in Omnicell by 156.4% in the 4th quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock worth $94,014,000 after purchasing an additional 1,265,818 shares during the period. Lazard Asset Management LLC grew its holdings in Omnicell by 3.8% during the 2nd quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock valued at $50,225,000 after buying an additional 62,733 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Omnicell by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 1,127,583 shares of the company’s stock valued at $51,088,000 after buying an additional 11,424 shares during the period. Finally, Millennium Management LLC bought a new stake in shares of Omnicell during the third quarter valued at about $25,625,000. 97.70% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on OMCL. Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 10th. Wells Fargo & Company increased their price objective on shares of Omnicell from $52.00 to $55.00 and gave the company an “overweight” rating in a research note on Thursday, April 23rd. Weiss Ratings raised shares of Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research report on Thursday, May 7th. Zacks Research downgraded Omnicell from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Finally, Craig Hallum reaffirmed a “buy” rating and issued a $55.00 target price on shares of Omnicell in a report on Wednesday, April 29th. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Omnicell presently has a consensus rating of “Moderate Buy” and a consensus price target of $59.86.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.